NCT00769132View on ClinicalTrials.gov

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2007

Primary Completion Date

October 13, 2007

Study Completion Date

November 6, 2007

Conditions

Hypercholesterolemia

Interventions

DRUG

Comparator: niacin + laropiprant

ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days

DRUG

Comparator: niacin

ER niacin 2 g tablet once daily for 7 days

DRUG

Comparator: laropiprant

laropiprant 40 mg once daily for 7 days

DRUG

Comparator: placebo

matching placebo tablets for each of the interventions once daily for 7 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00769132 - A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) | Biotech Hunter | Biotech Hunter